Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
26 hedge funds and large institutions have $75.3M invested in Cymabay Therapeutics in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
112% more capital invested
Capital invested by funds: $35.6M → $75.3M (+$39.7M)
53% more funds holding
Funds holding: 17 → 26 (+9)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$6.01M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.59M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.87M |
| 4 |
VAM
Visium Asset Management
New York
|
+$2.73M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$953K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.51M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.61M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.2M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$804K |
| 5 |
Jennison Associates
New York
|
-$52.3K |
CBAY Hedge Fund Activity: Q4 2014 in Review
26 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2014, worth a combined $75.3M — up 112% from $35.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CBAY positions and 3 closed out — a net gain of 9 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $6.01M. The largest seller was Deerfield Management, exiting entirely with an estimated $3.51M sold.
- 26 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2014, up from 17 in Q3 2014.
- Funds reported $75.3M of Cymabay Therapeutics stock for Q4 2014, up 112% quarter-over-quarter.
- 12 funds opened new Cymabay Therapeutics positions in Q4 2014 and 3 closed out, a net change of +9 holders.
- The largest Cymabay Therapeutics buyer in Q4 2014 was EverPoint Asset Management, an estimated $6.01M added.
- The largest Cymabay Therapeutics seller in Q4 2014 was Deerfield Management, an estimated $3.51M sold.
Based on aggregated 13F filings for Q4 2014.